Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

PureTech (PRTC)

Price 213.50p on 23-02-2024 at 17:53:08
Change 22.10p 11.55%
Buy 214.00p
Sell 212.00p
Buy / Sell PRTC Shares
Last Trade: Unknown 22,632.00 at 213.50p
Day's Volume: 1,723,414
Last Close: 213.50p
Open: 195.00p
Day's Range 193.20p - 214.00p
52wk Range: 139.00p - 242.00p
Market Capitalisation: £576m
VWAP: 205.10842p
Shares in Issue: 270m

Recent Trades History PureTech (PRTC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 22,632 213.50p Currency Conversion
OTC Trade
17:52:34 - 23-Feb-24
Unknown* 47,870 208.621p Currency Conversion
OTC Trade
17:31:38 - 23-Feb-24
Unknown* 8,927 203.843p Currency Conversion
OTC Trade
17:22:01 - 23-Feb-24
Unknown* 2,311 205.322p Currency Conversion
OTC Trade
17:09:10 - 23-Feb-24
Unknown* 4,419 213.498p Currency Conversion
OTC Trade
17:07:52 - 23-Feb-24
Unknown* 94,291 213.50p Currency Conversion
OTC Trade
17:05:11 - 23-Feb-24
Unknown* 1,315 209.023p Currency Conversion
OTC Trade
16:57:13 - 23-Feb-24
Unknown* 1,621 213.511p Currency Conversion
OTC Trade
16:56:42 - 23-Feb-24
Unknown* 46 213.50p Currency Conversion
OTC Trade
16:53:38 - 23-Feb-24
Buy* 230,183 213.50p Suspected BUY Trade
16:35:01 - 23-Feb-24

Share Price History for PureTech

Time period:
Date Open High Low Close Volume

Share News for PureTech

PureTech makes strong progress, expects "multiple catalysts" next year

20th Dec 2023 09:53

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come. Read More

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

1st Dec 2023 14:29

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News: Read More

IN BRIEF: PureTech hails schizophrenia trial results for Karuna drug

17th Nov 2023 09:44

PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease. Read More

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell. Read More

PureTech Health celebrates positive results in Phase 2 anxiety trial

14th Nov 2023 10:59

(Alliance News) - PureTech Health PLC on Tuesday said its therapeutic LYT-300 achieved its primary endpoint for acute anxiety reduction, in a Phase 2a trial using healthy volunteers. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered